The Prostacyclin International Expert Panel developed consensus opinions on common clinical scenarios in which they considered adding an oral prostacyclin pathway agent in pulmonary arterial hypertension (PAH) patients. This interactive, Virtual Learning Theater will feature a group of the authors who will discuss the results of the consensus survey.
This is a non-CME educational program sponsored by Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.
Vallerie V. McLaughlin, MD
University of Michigan
Ann Arbor, Michigan
Ioana Preston, MD
Tufts University School of Medicine
Email contact for questions: [email protected]